S
Suzhou Xinkanghe Biomedical Technology
First-in-class antibody therapies for cancer and autoimmune diseases
About Suzhou Xinkanghe Biomedical Technology
Suzhou Xinkanghe Biomedical Technology (Kanovabiopharma) is a biopharmaceutical company established in November 2015 with its headquarters in BioBAY, Suzhou. The company focuses on the research and development of innovative antibody drugs for oncology and inflammatory diseases. Kanovabiopharma was founded by a world-renowned immunologist and aims to develop first-in-class therapeutic antibodies and novel combination therapies.
The company's scientific advisory board is led by Professor Chen Dong, a prominent immunologist recognized for his discovery of Th17 cells and their role in immune diseases. The leadership team includes CEO Yaning Wang, who has 30 years of experience in pharmaceutical companies, and SVP Dr. Li Guo, who has 20 years of experience in novel biologics discovery.
Kanovabiopharma's pipeline includes several antibody drug candidates. Its IL-17A/F antibody has reached the primary endpoint in a Phase III clinical trial for ankylosing spondylitis. Another key drug, XKH001, received FDA approval for clinical trials. The company's business model revolves around in-house research and development, strategic collaborations, and out-licensing of its assets, such as the XKH004 program. It operates in the global biopharmaceutical market, addressing unmet medical needs in immunology. The company has successfully raised capital through multiple financing rounds, including Pre-A, A, B, and B+ rounds to fund its research and clinical programs.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jul 2023 | $14M | $55M | ShenZhen GTJA Investment Group | ↗ |
Growth signals
Latest recorded traffic for Suzhou Xinkanghe Biomedical Technology is 440 monthly website visits, down 38.9% over the last three months. Suzhou Xinkanghe Biomedical Technology's team grew 0% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Suzhou Xinkanghe Biomedical Technology in its local ecosystem
The Suzhou Xinkanghe Biomedical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- SGShenZhen GTJA Investment Group
Other known investors2 additional known investors
3H Health Investment
CD Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Suzhou Xinkanghe Biomedical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Suzhou Xinkanghe Biomedical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.